Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

305 results about "Serine Protease Inhibitors" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Serpins are a superfamily of proteins with similar structures that were first identified for their protease inhibition activity and are found in all kingdoms of life. The acronym serpin was originally coined because the first serpins to be identified act on chymotrypsin-like serine proteases (serine protease inhibitors).

Macrocyclic hepatitis C serine protease inhibitors

InactiveUS20050153877A1BiocideAntiviralsHepatitis c viralPharmaceutical medicine

The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:

wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis C serine protease inhibitors

Owner:ENANTA PHARM INC

Peptides as NS3-serine protease inhibitors of hepatitis C virus

InactiveUS7012066B2Organic active ingredientsDigestive systemSerine Protease InhibitorsHepatitis C virus

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Owner:DENDREON PHARMA INC +1

Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus

InactiveUS6911428B2BiocideAntiviralsSerine Protease InhibitorsCrystallography

The present invention is directed to certain diaryl amide compounds as NS3-Serine protease inhibitors of hepatitis C virus. A particularly preferred compound is of the formula:

Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus

Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus

Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus

Owner:SCHERING CORP

Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus

InactiveUS6838475B2Reduce frictionReduce wearBiocideOrganic active ingredientsSerine Protease InhibitorsHepacivirus

The present invention discloses novel imidazolidinones which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazolidinones as well as methods of using them to treat disorders associated with the HCV protease.

Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus

Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus

Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus

Owner:SCHERING CORP

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

InactiveUS20050176648A1BiocideDipeptide ingredientsSerine Protease InhibitorsHepatitis C virus

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

Owner:MERCK SHARP & DOHME CORP +1

Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties

InactiveUS6846802B2BiocideAntiviralsSerine Protease InhibitorsHepatitis C virus

The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such macrocycles as well as methods of using them to treat disorders associated with the HCV protease.

Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties

Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties

Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties

Owner:SCHERING CORP

Five-membered heterocycles useful as serine protease inhibitors

ActiveUS20050282805A1BiocideOrganic chemistryFactor VIIaKinin

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V):

or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R³, R⁴, R⁶, R¹¹, X¹, X², and X³are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

Five-membered heterocycles useful as serine protease inhibitors

Five-membered heterocycles useful as serine protease inhibitors

Five-membered heterocycles useful as serine protease inhibitors

Owner:BRISTOL MYERS SQUIBB CO

Peptides as NS3-serine protease inhibitors of hepatitis C virus

InactiveUS7169760B2BiocideDipeptide ingredientsDiseaseSerine Protease Inhibitors

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Owner:DENDREON PHARMA LLC +1

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

ActiveUS7176208B2BiocideAntiviralsSerine Protease InhibitorsProteinase activity

The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

Owner:ENANTA PHARM INC

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

InactiveUS7273885B2Inhibit HCV replicationReduce riskBiocidePeptide/protein ingredientsHepatitis c viralSerine Protease Inhibitors

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Owner:VERTEX PHARMA INC

Peptides as NS3-serine protease inhibitors of hepatitis C virus

InactiveUS7244721B2BiocideDigestive systemDiseaseSerine Protease Inhibitors

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Peptides as NS3-serine protease inhibitors of hepatitis C virus

Owner:DENDREON PHARMA LLC +1

Macrocyclic Proline Derived HCV Serine Protease Inhibitors

ActiveUS20120070416A1Antibacterial agentsBiocideSerine Protease InhibitorsIsrapafant

The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Macrocyclic Proline Derived HCV Serine Protease Inhibitors

Macrocyclic Proline Derived HCV Serine Protease Inhibitors

Macrocyclic Proline Derived HCV Serine Protease Inhibitors

Owner:ENANTA PHARM INC

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

ActiveUS20070060510A1Organic active ingredientsBiocideSerine Protease InhibitorsProteinase activity

The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

Owner:ENANTA PHARM INC

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

InactiveUS20070032433A1BiocideTripeptide ingredientsSerine Protease InhibitorsDisease

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

Owner:DENDREON PHARMA LLC +1

Peptide inhibitors of Hepatitis C virus NS3 protease

InactiveUS6846806B2Peptide/protein ingredientsOrganic compound preparationSerine Protease InhibitorsProteinase activity

This invention relates to a novel class of peptides having the Formula (I):

which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

Peptide inhibitors of Hepatitis C virus NS3 protease

Peptide inhibitors of Hepatitis C virus NS3 protease

Peptide inhibitors of Hepatitis C virus NS3 protease

Owner:BRISTOL MYERS SQUIBB CO

Bridged bicyclic serine protease inhibitors

InactiveUS6909000B2Inhibit HCV replicationReduce riskBiocidePeptide/protein ingredientsSerine Protease InhibitorsProteinase activity

The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

Bridged bicyclic serine protease inhibitors

Bridged bicyclic serine protease inhibitors

Bridged bicyclic serine protease inhibitors

Owner:VERTEX PHARMA INC

Macrocyclic hepatitis C serine protease inhibitors

ActiveUS20100144608A1Organic active ingredientsBiocideSerine Protease InhibitorsExcipient

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis C serine protease inhibitors

Owner:ABBVIE INC +1

Compounds as NS3-serine protease inhibitors of hepatitis C virus

InactiveUS6894072B2BiocideOrganic chemistrySerine Protease InhibitorsHepatitis C virus

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Compounds as NS3-serine protease inhibitors of hepatitis C virus

Compounds as NS3-serine protease inhibitors of hepatitis C virus

Compounds as NS3-serine protease inhibitors of hepatitis C virus

Owner:MERCK SHARP & DOHME CORP

Inhibitors of serine proteases

InactiveUS20070105781A1Reduce riskReduce severityBiocideOrganic active ingredientsMedicinal chemistrySerine

This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers wherein the R isomer is greate than 50% of the mixture.

Inhibitors of serine proteases

Inhibitors of serine proteases

Inhibitors of serine proteases

Owner:VERTEX PHARMA INC

Biaryl compounds as serine protease inhibitors

InactiveUS6699994B1Organic chemistryPeptide/protein ingredientsSerine Protease InhibitorsFactor VIIa

Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.

Biaryl compounds as serine protease inhibitors

Biaryl compounds as serine protease inhibitors

Biaryl compounds as serine protease inhibitors

Owner:BIOCRYST PHARM INC

Novel inhibitors of hepatitis C virus NS3/NS4a serine protease

InactiveUS20050153900A1Symptoms improvedOrganic active ingredientsBiocideDiseaseSerine Protease Inhibitors

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Novel inhibitors of hepatitis C virus NS3/NS4a serine protease

Novel inhibitors of hepatitis C virus NS3/NS4a serine protease

Novel inhibitors of hepatitis C virus NS3/NS4a serine protease

Owner:SCHERING CORP

Hydrazide-containing hepatitis c serine protease inhibitors

ActiveUS20080269228A1Inhibitory activityBiocidePeptidesPharmaceutical medicineHcv hepatitis

The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Hydrazide-containing hepatitis c serine protease inhibitors

Hydrazide-containing hepatitis c serine protease inhibitors

Hydrazide-containing hepatitis c serine protease inhibitors

Owner:ENANTA PHARM INC

Phosphorus-containing hepatitis C serine protease inhibitors

InactiveUS20080039375A1Inhibit serine protease activityInhibitory activityBiocideDipeptide ingredientsSerine protease activitySerine

The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Phosphorus-containing hepatitis C serine protease inhibitors

Phosphorus-containing hepatitis C serine protease inhibitors

Phosphorus-containing hepatitis C serine protease inhibitors

Owner:ENANTA PHARM INC

Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors

InactiveUS20080279821A1BiocideHydrocarbon active ingredientsSerine Protease InhibitorsProteinase activity

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors

Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors

Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors

Owner:ENANTA PHARM INC

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

InactiveUS20050065073A1BiocideAntiviralsSerine Protease InhibitorsProteinase activity

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

Owner:ENANTA PHARM INC

Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors

InactiveUS20090005387A1Inhibit serine protease activityInhibitory activityBiocideOrganic chemistrySerine Protease InhibitorsProteinase activity

The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors

Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors

Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors

Owner:ENANTA PHARM INC

Peptide inhibitors of hepatitis C virus NS3 protease

InactiveUS6939854B2BiocideDigestive systemSerine Protease InhibitorsProteinase activity

This invention relates to a novel class of peptides having the Formula (I): which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus (HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

Peptide inhibitors of hepatitis C virus NS3 protease

Peptide inhibitors of hepatitis C virus NS3 protease

Peptide inhibitors of hepatitis C virus NS3 protease

Owner:BRISTOL MYERS SQUIBB PHARMA CO

N-functionalized amides as hepatitis c serine protease inhibitors

InactiveUS20080267917A1Inhibitory activityAntibacterial agentsBiocideHepatitis c viralPharmaceutical medicine

The present invention relates to functionalized amides of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

N-functionalized amides as hepatitis c serine protease inhibitors

N-functionalized amides as hepatitis c serine protease inhibitors

N-functionalized amides as hepatitis c serine protease inhibitors

Owner:ENANTA PHARM INC

Macrocyclic hepatitis C serine protease inhibitors

InactiveUS7601709B2BiocideAntiviralsSerine Protease InhibitorsProteinase activity

The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis C serine protease inhibitors

Owner:ENANTA PHARM INC

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

InactiveUS7125845B2BiocideAntiviralsSerine Protease InhibitorsProteinase activity

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

Owner:ENANTA PHARM INC

Popular searches

Pharmaceutical Substances Hepatitis viral c Prodrug Proteinase inhibitor NS3 Virus resistance HCV Positive Molecular biology Serine protease Stereochemistry

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap